Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 10, 2015, Pages 1845-1857

  Stoker, Sharon D ^a   Novalić, Zlata ^b   Wildeman, Maarten A ^a,c   Huitema, Alwin D R ^a   Verkuijlen, Sandra A W M ^b   Juwana, Hedy ^b   Greijer, Astrid E ^b   Tan, I Bing ^a,c,d   Middeldorp, Jaap M ^b   de Boer, Jan Paul ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

Advanced disease; Epstein Barr virus; Metastatic disease; Nasopharyngeal carcinoma; Targeted therapy

Indexed keywords

GANCICLOVIR; GEMCITABINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VALGANCICLOVIR; VALPROIC ACID; VIRUS DNA; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; VIRUS ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FATIGUE; FEMALE; HEADACHE; HEARING IMPAIRMENT; HUMAN; IMMUNE RESPONSE; LIVER METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA DISEASE; PLEURAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; T LYMPHOCYTE; VIROLOGY; VIRUS LATENCY;

ADULT; ANTIBODIES, VIRAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES; VALPROIC ACID; VIRUS LATENCY;

EID: 84939563353     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1969-3     Document Type: Article

References (55)

1. Adham M, Greijer AE, Verkuijlen SA, Juwana H, Fleig S, Rachmadi L et al (2013) Epstein–Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment. Clin Cancer Res 19(8):2175–2186
2. Adham M, Stoker SD, Wildeman MA, Rachmadi L, Gondhowiardjo S, Atmakusumah D et al (2014) Current status of cancer care for young patients with nasopharyngeal carcinoma in Jakarta, Indonesia. PLoS ONE 9(7):e102353
3. Andersen RS, Kvistborg P, Frosig TM, Pedersen NW, Lyngaa R, Bakker AH et al (2012) Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 7(5):891–902
4. Arnold M, Wildeman MA, Visser O, Karim-Kos HE, Middeldorp JM, Fles R et al (2013) Lower mortality from nasopharyngeal cancer in The Netherlands since 1970 with differential incidence trends in histopathology. Oral Oncol 49(3):237–243
5. Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H et al (2011) Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 128(2):79–85
6. Boom R, Sol C, Weel J, Gerrits Y, de Boer M (1999) Wertheim-van Dillen P. A highly sensitive assay for detection and quantitation of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence. J Clin Microbiol 37(5):1489–1497
7. Chan KC, Lo YM (2002) Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 12(6):489–496
8. Chen MY, Jiang R, Guo L, Zou X, Liu Q, Sun R et al (2013) Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chin J Cancer 32(11):604–613
9. Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM et al (2014) Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22(1):132–139
10. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR et al (2006) Single-assay combination of Epstein–Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol 44(4):1459–1467
11. Fachiroh J, Prasetyanti PR, Paramita DK, Prasetyawati AT, Anggrahini DW, Haryana SM et al (2008) Dried-blood sampling for Epstein–Barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening. J Clin Microbiol 46(4):1374–1380
12. Faller DV, Mentzer SJ, Perrine SP (2001) Induction of the Epstein–Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein–Barr virus-associated malignancies. Curr Opin Oncol 13(5):360–367
13. Feng WH, Kenney SC (2006) Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 66(17):8762–8769
14. Feng WH, Hong G, Delecluse HJ, Kenney SC (2004) Lytic induction therapy for Epstein–Barr virus-positive B-cell lymphomas. J Virol 78(4):1893–1902
15. Ghosh SK, Perrine SP, Faller DV (2012a) Advances in virus-directed therapeutics against Epstein–Barr virus-associated malignancies. Adv Virol 2012:509296
16. Ghosh SK, Perrine SP, Williams RM, Faller DV (2012b) Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 119(4):1008–1017
17. Greijer AE, Stevens SJ, Verkuijlen SA, Juwana H, Fleig SC, Verschuuren EA et al (2012) Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients. Clin Dev Immunol 2012:543085
18. Hesselink AT, van den Brule AJ, Groothuismink ZM, Molano M, Berkhof J, Meijer CJ et al (2005) Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol 43(9):4868–4871
19. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: lessons from Epstein–Barr virus. Annu Rev Immunol 25:587–617
20. Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, Jin YT et al (2010) Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol 23(10):1393–1403
21. Hutajulu SH, Kurnianda J, Tan IB, Middeldorp JM (2014) Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma. Ther Clin Risk Manag 10:721–736
22. Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souquere S, Nishi N, Hirashima M et al (2006) Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 6:283
23. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D et al (2014) Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 6(254):254ra128
24. Le QT, Zhang Q, Cao H, Cheng AJ, Pinsky BA, Hong RL et al (2013) An international collaboration to harmonize the quantitative plasma Epstein–Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res 19(8):2208–2215
25. Lee AW, Lin JC, Ng WT (2012) Current management of nasopharyngeal cancer. Semin Radiat Oncol 22(3):233–244
26. Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M et al (2006) Plasma Epstein–Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 24(34):5414–5418
27. Leung SF, Chan KC, Ma BB, Hui EP, Mo F, Chow KC et al (2014) Plasma Epstein–Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 25(6):1204–1208
28. Li JH, Huang D, Sun BF, Zhang X, Middeldorp J, Klamut H et al (2000) Efficacy of ionizing radiation combined with adenoviral p53 therapy in EBV-positive nasopharyngeal carcinoma. Int J Cancer 87(4):606–610
29. Li J, Zhang XS, Xie D, Deng HX, Gao YF, Chen QY et al (2007a) Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression. Cancer Biol Ther 6(12):1997–2004
30. Li J, Zeng XH, Mo HY, Rolen U, Gao YF, Zhang XS et al (2007b) Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS ONE 2(11):e1122
31. Lima RT, Seca H, Bras S, Nascimento MS, Vasconcelos MH (2011) Treatment of Akata EBV-positive cells with doxorubicin causes more EBV reactivation than treatment with etoposide. Chemotherapy 57(3):195–203
32. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT et al (2010) Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33(9):983–990
33. Lutzky VP, Crooks P, Morrison L, Stevens N, Davis JE, Corban M et al (2014) Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clin Vaccine Immunol 21(2):256–259
34. Merlo A, Turrini R, Dolcetti R, Zanovello P, Rosato A (2011) Immunotherapy for EBV-associated malignancies. Int J Hematol 93(3):281–293
35. Middeldorp JM, Herbrink P (1988) Epstein–Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J Virol Methods 21(1–4):133–146
36. Middeldorp JM, Pegtel DM (2008) Multiple roles of LMP1 in Epstein–Barr virus induced immune escape. Semin Cancer Biol 18(6):388–396
37. Middeldorp JM, Brink AA, Van Den Brule AJ, Meijer CJ (2003) Pathogenic roles for Epstein–Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 45(1):1–36
38. Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF (2001) Induction of Epstein–Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 45(7):2082–2091
39. Nordh S, Ansari D, Andersson R (2014) hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol 20(26):8482–8490
40. Perrine SP, Hermine O, Small T, Suarez F, O’Reilly R, Boulad F et al (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein–Barr virus-associated lymphoid malignancies. Blood 109(6):2571–2578
41. Secondino S, Zecca M, Licitra L, Gurrado A, Schiavetto I, Bossi P et al (2012) T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol 23(2):435–441
42. Stevens SJ, Verkuijlen SA, Middeldorp JM (2005a) Quantitative detection of Epstein–Barr virus DNA in clinical specimens by rapid real-time PCR targeting a highly conserved region of EBNA-1. Methods Mol Biol 292:15–26
43. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi FachirohJ, Paramita DK et al (2005b) Diagnostic value of measuring Epstein–Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 43(7):3066–3073
44. Stevens SJ, Zwaan CM, Verkuijlen SA, Middeldorp JM (2006a) Epstein–Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy. Head Neck 28(11):1040–1045
45. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi ParamitaDK, Fachiroh J et al (2006b) Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein–Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 119(3):608–614
46. Sun P, Chen C, Cheng YK, Zeng ZJ, Chen XL, Liu LZ et al (2014) Serologic biomarkers of Epstein–Barr virus correlate with TNM classification according to the seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 271(9):2545–2554
47. Vainchtein LD, Rosing H, Thijssen B, Schellens JH, Beijnen JH (2007) Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2′,2′-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom 21(14):2312–2322
48. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW et al (2002) Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99(12):4364–4369
49. Veltkamp SA, Hillebrand MJ, Rosing H, Jansen RS, Wickremsinhe ER, Perkins EJ et al (2006) Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J Mass Spectrom 41(12):1633–1642
50. Wang WY, Twu CW, Chen HH, Jan JS, Jiang RS, Chao JY et al (2010) Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 16(3):1016–1024
51. Wei WI, Sham JS (2005) Nasopharyngeal carcinoma. Lancet 365(9476):2041–2054
52. Wildeman MA, Novalic Z, Verkuijlen SA, Juwana H, Huitema AD, Tan IB et al (2012) Cytolytic virus activation therapy for Epstein–Barr virus driven tumours. Clin Cancer Res 18(18):5061–5070
53. Wildeman MA, Fles R, Herdini C, Indrasari RS, Vincent AD, Tjokronagoro M et al (2013) Primary treatment results of nasopharyngeal carcinoma (NPC) in Yogyakarta, Indonesia. PLoS ONE 8(5):e63706
54. Yip WK, Abdullah MA, Yusoff SM, Seow HF (2009) Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Clin Exp Immunol 155(3):412–422
55. Zheng Y, Dou Y, Duan L, Cong C, Gao A, Lai Q et al (2015) Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol 294(1):54–59